Brokerages Set Guardant Health, Inc. (NASDAQ:GH) Target Price at $39.67

Shares of Guardant Health, Inc. (NASDAQ:GHGet Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $39.67.

Several equities research analysts have recently issued reports on GH shares. Bank of America raised their price objective on Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, July 18th. UBS Group increased their price target on Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 21st. Craig Hallum increased their price target on Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Guggenheim upgraded Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 price target on the stock in a report on Friday, June 28th. Finally, JPMorgan Chase & Co. increased their price target on Guardant Health from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th.

Get Our Latest Stock Report on Guardant Health

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Handelsbanken Fonder AB increased its holdings in shares of Guardant Health by 14.8% in the 3rd quarter. Handelsbanken Fonder AB now owns 27,141 shares of the company’s stock valued at $623,000 after acquiring an additional 3,500 shares during the period. SG Americas Securities LLC purchased a new position in shares of Guardant Health in the 3rd quarter valued at $1,029,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Guardant Health in the 2nd quarter valued at $71,000. Truist Financial Corp purchased a new position in shares of Guardant Health in the 2nd quarter valued at $233,000. Finally, Quarry LP purchased a new position in shares of Guardant Health in the 2nd quarter valued at $44,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Guardant Health Price Performance

NASDAQ:GH opened at $22.16 on Wednesday. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of -5.65 and a beta of 1.11. Guardant Health has a 1 year low of $15.81 and a 1 year high of $37.04. The business has a 50 day simple moving average of $26.92 and a 200-day simple moving average of $25.38. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.40 and a quick ratio of 6.07.

Guardant Health (NASDAQ:GHGet Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). The company had revenue of $177.24 million during the quarter, compared to the consensus estimate of $162.59 million. Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. Guardant Health’s revenue for the quarter was up 29.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.67) earnings per share. Equities analysts forecast that Guardant Health will post -3.31 EPS for the current year.

Guardant Health Company Profile

(Get Free Report

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Further Reading

Analyst Recommendations for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.